Cargando…
Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol
BACKGROUND: Biological therapy is a cornerstone of managing moderate-to-severe inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD). New biologics have been evolving over the past 20 years and selection of an agent remains challenging. Drug persistence measures the dura...
Autores principales: | Yiu, Tsz Hong, Ko, Yanna, Pudipeddi, Aviv, Natale, Patrizia, Leong, Rupert W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551959/ https://www.ncbi.nlm.nih.gov/pubmed/37788929 http://dx.doi.org/10.1136/bmjopen-2023-073071 |
Ejemplares similares
-
Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol
por: Johnston, Amy, et al.
Publicado: (2018) -
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
por: Pudipeddi, Aviv, et al.
Publicado: (2022) -
Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial
por: Bouhuys, Marleen, et al.
Publicado: (2021) -
Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial
por: Au, Michael, et al.
Publicado: (2023) -
Persistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT)
por: Löwe, Bernd, et al.
Publicado: (2022)